Pemoline in the Treatment of Stimulant Dependence - 5

This study has been withdrawn prior to enrollment.
(Study was never funded.)
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000340
First received: September 20, 1999
Last updated: August 25, 2008
Last verified: August 2008

September 20, 1999
August 25, 2008
June 1996
Not Provided
  • Retention
  • Depression
  • Incidence of stimulant use
  • Severity of stimulant withdrawal symptoms
  • ADHD symptom severity
  • Degree of drug craving
  • Frequency of IV drug use and sexual risk behaviors
Same as current
Complete list of historical versions of study NCT00000340 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Pemoline in the Treatment of Stimulant Dependence - 5
Pemoline in the Treatment of Stimulant Dependence

The purpose of this study is to assess the efficacy of pemoline in treating cocaine and/or methamphetamine dependent adults with comorbid Adult Attention Deficit Hyperactivity Disorder (ADHD).

Not Provided
Interventional
Phase 2
Primary Purpose: Treatment
Cocaine-Related Disorders
Drug: Pemoline
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
1
Not Provided
Not Provided

Inclusion Criteria:

M/F ages 21-50. Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the study and sign informed consent.

Exclusion Criteria:

Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.

Both
21 Years to 50 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00000340
NIDA-3-0010-5, Y01-3-0010-5
Not Provided
Not Provided
National Institute on Drug Abuse (NIDA)
Not Provided
Principal Investigator: Walter Ling, M.D. Friends Research Institute, Inc.
National Institute on Drug Abuse (NIDA)
August 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP